Log In Create an Account
  • Home
  • Contact us
  • SCAI.org Home |
  • SecondsCount.org |
  • eLearning Library |
  • Donate |
  • my.scai.org|
  • SCAI Store
  • My SCAI
  • My Community
  • Member Directory
 Menu
  • About SCAI
    • History
    • SCAI Code of Ethics
    • Board of Trustees
    • Committees and Councils
    • International Ambassadors
    • Marketing Opportunities
    • Bylaws for SCAI 501(c)(6)
    • Bylaws for SCAI 501(c)(3)
    • Distinguished Service Awards
    • SCAI Helping Hearts Lifetime Service Award
    • Patient Education & Collaboration
    • Employment Opportunities
    • Corporate Community
    • Contact Us
    • Terms & Conditions
  • Membership
    • Join SCAI
    • Membership Update FAQs
    • Member Directory
    • Master Interventionalists of SCAI (MSCAI)
    • International
  • Education & Meetings
    • Events Calendar
    • SCAI Scientific Sessions
    • SCAI SHOCK
    • Fall Fellows
    • Board Prep & Self-Assessment
    • Maintenance of Certification (MOC)
    • eLearning Library
    • Co-Provided Programs
  • Documents & Quality
    • Clinical Documents & Guidelines
    • Quality Improvement Toolkit
    • Point-of-Care Apps
    • SCAI PAD Diagnosis & Treatment Resource Center
    • TRAnsition for VALUE
    • Heart Valve Initiative
    • Vascular Access eBook
    • SCAI Shock Resource Center
    • MIPS Resource Center
    • Cath Lab Survey Program
    • Choosing Wisely
    • Cardiovascular Cath Accreditation
  • Advocacy
    • Interventional Cardiology Designation
    • Contribute to SCAI PAC
    • Advocacy News
    • Coding & Reimbursement
    • Device & Drug Safety
  • Careers & Fellows
    • FIT Core Curriculum
    • SCAI Career Center
    • Emerging Leader Mentorship (ELM) Program
    • Pediatric Interventional Cardiology Early Career Society (PICES)
    • FIT & Early Career Membership
    • U.S. Based Structural Training Programs
    • SCAI-WIN CHIP Fellowship
  • News
    • Press Releases
    • About SCAI
    • CCI Journal
    • SCAI This Week eBrief
    • President's Pages
    • Press Contacts
    • SCAI TV
    • Social Media Help Center
  • Clinical Interests
    • COVID-19 Resources
    • Congenital Interest Section
    • Coronary Interest Section
    • SCAI Imaging Center
    • Peripheral Interest Section
    • Structural & Valvular Interest Section
    • SCAI TAVR Center
    • SCAI Heart Failure Center
    • Submit Your Image Review
 Sections
  • COVID-19 Resources
  • Congenital Interest Section
  • Coronary Interest Section
  • SCAI Imaging Center
  • Peripheral Interest Section
  • Structural & Valvular Interest Section
  • SCAI TAVR Center
    • TAVR Documents & Resources
    • Journal Scan
    • Image Review
    • Journal Club
    • Cath Conference
  • SCAI Heart Failure Center
  • Submit Your Image Review
  • TAVR Image Reviews

    CLICK HERE to access the latest SCAI TAVR Center Image Reviews.

  • Get Involved! Submit Your Image Review Presentation

    Want to submit your original clinical case study to a SCAI.org Clinical Interest Section?

    CLICK HERE to learn more about how to submit your Image Review presentation.

  • TAVR Documents & Resources

    Additional TAVR resources including critical publications and links to live programming and other training options:

    • SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement. Part II. Mitral Valve

    • STS/ACC TVT Registry Home

    CLICK HERE TO ACCESS MORE!

  • SCAI TAVR Center
    Supported by:Medtronic

  • SCAI TAVR CENTER features a variety of resources aimed at helping interventional cardiologists and other heart team members become proficient in transcatheter aortic valve replacement (TAVR) whether you are at a beginner or advanced training level.
     

  • WHAT'S NEW

    FDA Approves Recapturable, Self-expandable TAVR System

    Cardiology Today's Intervention: On June 23 Medtronic announced that it has received Food and Drug Administration approval for a new recapturable, self-expanding system for transcatheter aortic valve replacement for treatment of patients with severe aortic stenosis who are at high or extreme risk for surgery. The CoreValve Evolut R System device is the first recapturable, self-expanding, transcatheter heart valve approved in the United States. CONTINUE TO STORY

     


    FDA Approves SAPIEN 3 THV Artificial Heart Valve

    FDA: On June 17, the U.S. Food and Drug Administration today approved the SAPIEN 3 Transcatheter Heart Valve (THV) for patients with a narrowing in the heart's aortic valve, called aortic valve stenosis. The SAPIEN 3 THV is approved for patients with aortic valve stenosis who are inoperable or at high risk for death or complications associated with open-heart surgery. ADDITIONAL INFORMATION

     


    Building a Better Valve

    New York Times: The New York Times profiles the TAVR story, a wonderful example of a transformative technology that began with an idea many dismissed. This story also illustrates how TAVR is part of the changing face of cardiac care in the United States. READ ON

     


    Image Review

    What Happened to the Valve?
    Daniel H. Steinberg, MD reviews a rare case of Ventricular Embolization the case of an 89 year old patient with a history of chronic systolic heart failure. This case features lots of learning points. REVIEW

     


    Image Review

    Coronary Obstruction During Transcatheter Aortic Valve Replacement
    Christian Spies, MD, FSCAI reviews this rare case, discussing the factors of coronary obstruction in TAVR and several take home points. TAKE A LOOK

    Previously in CCI

    • Core Curriculum: How to perform transcaval access and closure for transcatheter aortic valve implantation

    • Original Study: Femoral access-related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure

    • Editorial Comment: One step forward or eight needles back: A retro(grade) approach to femoral hemostasis for TAVR

    • Original Study: Transcatheter closure of postmyocardial infarction, iatrogenic, and postoperative ventricular septal defects: The Mayo Clinic experience

    • Original Study: Poor mobility predicts adverse outcome better than other frailty indices in patients undergoing transcatheter aortic valve implantation

    • Editorial Comment: Poor mobility independently predicts mortality in TAVI: Are we closer to a universal definition for frailty?

     

  • LOG IN New to SCAI?
    Setup your Login here
  • The SCAI TAVR Center is supported through an educational grant from Platinum Sponsor Medtronic. The Society gratefully acknowledges this support, while taking sole responsibility for all content developed and disseminated through this effort.

  • July Journal Scan

    Journal Scan provides a survey of the month's top cardiology journal's TAVR-related publications.

    Read the review of this top article in JACC: Cardiovascular Interventions and more: 
    2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement

    Journal Scan Archive

  • Summer Poll

    Summer Poll

    With the introduction of the Corevalve Evolut R and the Sapien 3, who do you believe TAVR should be offered to?
    Intermediate-risk (STS predicted mortality 4-8%) AS patients
    Intermediate-risk AS patients older than 70 years
    Low-risk (STS predicted mortality < 4%) AS patients
    Low risk AS patients older than 70 years
    High-risk patients only
      Results
  • SCAI TAVR Center Editors

    James B. Hermiller, MD, FSCAI
    View Bio

     

    Kreton Mavromatis, MD, FSCAI
    View Bio

     

     

    Featuring contributions by:

    SCAI.org Structural & Valvular Clinical Interest Section Editors

    George S. Hanzel, MD, FSCAI
    Senior Associate Editor
    View Bio

    Ramesh Daggubati, MD, FSCAI
    Associate Section Editor
    View Bio

    Chad A. Kliger, MD
    Associate Section Editor
    View Bio

    Daniel H. Steinberg, MD, FSCAI
    Associate Section Editor
    View Bio

     

SCAI® is a registered trademark of The Society for Cardiovascular Angiography and Interventions.

The Society for Cardiovascular Angiography and Interventions, 1100 17th Street NW, Suite 400, Washington, DC 20036

Phone: 202-741-9854 | Toll Free: 800-992-7224 | Fax: 202-689-7224 | Email: info@scai.org

Terms & Conditions

 

* Required
* First Name:
* Last Name:
Member ID:
* Phone Number:
* Email:
* Enter code:
* Message:
 

Thank you

Your feedback has been sent.